Engineering blood cells and proteins as blood substitutes: A short review

Biotechnology and Bioprocess Engineering

Volumn 12, Issue 1, 2007, Pages 43-47

  Kim, Hae Won ^a,b  

^a BROWN UNIVERSITY   (United States)

^b Biopure Corporation   (United States)

Author keywords

Artificial platelets; Blood substitutes; Hemoglobin based oxygen carriers; Red cell substitutes

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD SUBSTITUTE; CONJUGATED HEMOGLOBIN; EMULSIFYING AGENT; FIBRINOGEN; FLUOROCARBON; FRESH FROZEN PLASMA; HEMOGLOBIN; HEMOSPAN; HYBRID HEMOGLOBIN; LIPOSOME; MENINGITIS VACCINE; MP 4; PERFLUORODECALIN; PERFLUOROOCTYL BROMIDE; PERFLUOROTRIPROPYLAMINE; PLASMA PROTEIN; POLOXAMER; POLYGLYCOLIDE; POLYLACTIDE; POLYMERIZED HEMOGLOBIN; PROTHROMBIN; PYRIDOXYLHEMOGLOBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT HEMOGLOBIN; RECOMBINANT HUMAN SERUM ALBUMIN; RHESUS ANTIGEN; SMALLPOX VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; BIOENGINEERING; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; HEMATOLOGIC DISEASE; HEMODYNAMICS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MENINGITIS; NANOPHARMACEUTICS; NONHUMAN; OXYGEN AFFINITY; REVIEW; SICKLE CELL ANEMIA; SMALLPOX; THALASSEMIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; URINARY EXCRETION;

EID: 33847797129     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931802     Document Type: Review

References (30)

1. Kim, H. W. and A. G. Greenburg (2004) Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Artif. Organs 28: 813-828.
2. Scott, M. D., K. L. Murad, F. Koumpouras, M. Talbot, and J. W. Eaton (1997) Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc. Natl. Acad. Sci. USA 94:7566-7571.
3. Goldstein, J. (1989) Conversion of ABO blood groups. Transfus. Med. Rev. 3: 206-212.
4. Greenburg, A. G., M. Schooley, and G. W. Peskin (1977) Improved retention of stroma-free hemoglobin solution by chemical modification. J. Trauma 17: 501-504.
5. Bleeker, W. K., J. van der Plas, J. Agterberg, G. Rigter, and J. C. Bakker (1986) Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5′-phosphate. J. Lab. Clin. Med. 108: 448-455.
6. Sehgal, L. R., S. A. Gould, A. L. Rosen, H. L. Sehgal, and G. S. Moss (1984) Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery 95: 433-438.
7. Hsia, J. C. (1991) O-raffinose polymerized hemoglobin as a red cell substitute. Biomater. Artif. Cells Immobil. Biotechnol. 19: 401.
8. Greenburg, A. G. and H. W. Kim (2004) Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. J. Am. Coll. Surg. 198: 373-383.
9. Kim, H. W., B. A. Rowley, L. A. Roberts, et al. (1983) Bovine hemoglobin as a blood substitute. Proc. of IEEE Region 5 Conference. pp. 62-65.
10. Lee, R., N. Atsumi, E. E. Jacobs, Jr., W. G. Austen, and G. J. Vlahakes (1989) Ultrapure, stroma-free, polymerized bovine hemoglobin solution: evaluation of renal toxicity. J. Surg. Res. 47: 407-411.
11. Wong, J. T. (1988) Rightshifted dextran-hemoglobin as blood substitute. Biomater. Artif. Cells Artif. Organs 16: 237-245.
12. Iwashita, Y. (1992) Relationship between chemical properties and biological properties of pyridoxalated hemoglobin-polyoxyethylene. Biomater. Artif. Cells Immobilization Biotechnol. 20: 299-307.
13. Shorr, R. G. L. (1997) Abstract IA-05, 7th International Symposium on Blood Substitutes. September 7-10. Tokyo, Japan.
14. Vandegriff, K. D., A. Malavalli, J. Wooldrige, J. Lohman, and R. M. Winslow (2003) MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 43: 509-516.
15. Chang, T. M. (1998) Modified hemoglobin-based blood substitutes: crosslinked, recombinant and encapsulated hemoglobin. Vox Sang. 74 Suppl 2: 233-241.
16. Feola, M., J. Simoni, and R. Angelillo (2000) Abstract II-10, Eighth International Symposium on Blood Substitutes. November 9-11. San Diego, CA, USA.
17. Tsuchida, E., H. Nishide, M. Sekine, and A. Yamagishi (1983) Liposomal heme as oxygen carrier under semi-physiological conditions. Orientation study of heme embedded in a phospholipid bilayer by an electrooptical method. Biochim. Biophys. Acta 734: 274-278.
18. Yu, W. P. and T. M. S. Chang (1996) Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization. Artif. Cells Blood Substit. Immobil. Biotechnol. 24: 169-183.
19. Tsuchida, E., T. Komatsu, Y. Matsukawa, K. Hamamatsu, and J. Wu (1999) Human serum albumin incorporating Tetrakis(o-pivalamido) phenylporphinatoiron(II) derivative as a totally synthetic O2-carrying hemoprotein. Bioconjug. Chem. 10: 797-802.
20. Tsuchida, E., T. Komatsu, K. Hamamatsu, Y. Matsukawa, A. Tajima, A. Yoshizu, Y. Izumi, and K. Kobayashi (2000) Exchange transfusion with albumin-heme as an artificial O2-infusion into anesthetized rats: physiological responses, O2-delivery, and reduction of the oxidized hemin sites by red blood cells. Bioconjug. Chem. 11: 46-50.
21. Looker, D., D. Abbott-Brown, P. Cozart, S. Durfee, S. Hoffman, A. J. Mathews, J. Miller-Roehrich, S. Shoemaker, S. Trimble, G. Fermi, et al. (1992) A human recombinant haemoglobin designed for use as a blood substitute. Nature 356: 258-260.
22. Hayes, J. K., T. H. Stanley, G. H. Lind, K. East, B. Smith, and K. Kessler (2001) A double-blind study to evaluate the safety of recombinant human hemoglobin in surgical patients during general anesthesia. J. Cardiothoracic Vasc. Anesth. 15: 593-602.
23. Behringer, R. R., T. M. Ryan, M. P. Reilly, T. Asakura, R. D. Palmiter, R. L. Brinster, and T. M. Townes (1989) Synthesis of functional human hemoglobin in transgenic mice. Science 245: 971-973.
24. Keipert, P. E., N. S. Faithfull, D. C. Young, et al. (1997) Abstract IA-09, 7th International Symposium on Blood Substitutes. September 7-10. Tokyo, Japan.
25. Lundgren, C. E. G., G. W. Bergoe, and I. M. Tyssebotn (2003) Abstract F-I-4, Ninth International Symposium on Blood Substitutes. March 3-5. Tokyo, Japan.
26. Levi, M., P. W. Friederich, S. Middleton, P. G. de Groot, Y. P. Wu, R. Harris, B. J. Biemond, H. F. Heijnen, J. Levin, and J. W. ten Cate (1999) Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat. Med. 5: 107-111.
27. Teramura, Y., Y. Okamura, S. Takeoka, H. Tsuchiyama, H. Narumi, M. Kainoh, M. Handa, Y. Ikeda, and E. Tsuchida (2003) Hemostatic effects of polymerized albumin particles bearing rGPIa/IIa in thrombocytopenic mice. Biochem. Biophys. Res. Commun. 306: 256-260.
28. Bishop, P. and J. Lawson (2004) Recombinant biologics for treatment of bleeding disorders. Nat. Rev. Drug Discov. 3: 684-694.
29. Holliger, P. and H. R. Hoogenboom (1995) Artificial antibodies and enzymes: mimicking nature and beyond. Trends Biotechnol. 13: 7-9.
30. Enever, C., I. M. Tomlinson, J. Lund, M. Levens, and P. Holliger (2005) Engineering high affinity superantigens by phage display. J. Mol. Biol. 347: 107-120.